Background: In the ISAR-REACT 4 clinical trial in 1721 randomized patients undergoing percutaneous coronary angioplasty for non-ST elevation myocardial infarction, treatment with abciximab and heparin demonstrated an increased risk of bleeding in comparison to bivalirudin. However the results were not analyzed with respect to the age of the patients and it was not clear if this excess bleeding risk occurred in any particular sub-group. Methods: In this study, the patients from the ISAR REACT study were organized into four quartile groups according to age, and the outcomes analyzed with respect to treatment with abciximab and heparin or bivalirudin. The primary endpoint was the composite of death, large myocardial infarction, urgent target vessel revascularization or major bleeding within 30 days. The secondary endpoints were death, myocardial infarction or target vessel revascularization (efficacy endpoint) and major bleeding (safety endpoint) at 30 days. Results: A total of 1721 patients entered the study. The primary endpoint occurred in 11.8% vs. 11.6% in Q1, 10.2% vs. 9.8% in Q2, 10.7% vs. 10.3% in Q3 and 11.0% vs. 12.4% in Q4 in patients treated with abciximab and heparin or bivalirudin respectively. There was no overall interaction between age and occurrence of the primary endpoint (PINTERACTION ϭ0.81). There were no differences within the age quartile groups and no interaction between age and clinical outcome for the secondary efficacy endpoint (PINTERACTIONϭ0.84) or for the primary safety endpoint (PINTERACTIONϭ0.59) Conclusions: In patients undergoing treatment for non-ST elevation myocardial infarction and stratified by age, there were no differences in clinical outcome, safety or efficacy between those receiving abciximab and those receiving bivalirudin. This finding was consistent across a variety of key risk sub-groups.
Background: Randomized trials and registries have shown that everolimus-eluting stent (EES) performs better than first generation drug-eluting stent (DES). Prasugrel as compared to clopidogrel in acute coronary syndromes treated invasively is associated with improved clinical outcome and decreased risk of stent thrombosis. No data exist about prasugrel as compared to clopidogrel il patients with unprotected left main disease (ULMD) treated with EES. The aim of the study was to compare clinical outcome in patients receiving Clopidogrel or Prasugrel who underwent ULMD-PCI with EES. Methods: From the prospective Florence LM-PCI registry, consecutive patients receiving EES were included in the analysis. Antiplatelet treatment included clopidogrel until March 2010, while prasugrel was routinely used from April 2010. The end points of the study were cardiac mortality and stent thrombosis at 1 year of follow-up. Definite, probable and possible stent thromboses were defined according to the Academic Research Consortium criteria. Results: From January 2004 to 2011, 192 patients underwent EES implantation for ULMD. Out of these 94 pts received clopidogrel and 98 received prasugrel. Patients on prasugrel therapy had a worse baseline risk profile than patients on clopidogrel, but these differences did not reach statistical significance: mean age 70 Ϯ 10 vs. 71 Ϯ 11 yrs, male 78% vs. 75%, diabetes 28% vs. 21%, acute myocardial infarction 15% vs. 8%, left ventricular ejection fraction Ͻ0.40 40% vs. 32%, renal insufficiency (creatinine Ͼ 1.5 mg/dL) 15% vs. 8%, 3-vessel disease vs 35% vs 30%, EuroSCORE Ն13 31% vs. 21%. Procedural characteristics were similar in prasugrel group and clopidogrel group: LM stenting of both branches 30% vs. 28%, respectively, mean stent length (mm) 24 Ϯ 12 vs. 21 Ϯ 10, IVUS guidance 58% vs 56%. One-year clinical outcome was significantly better in the prasugrel group as compared to clopidogrel group: cardiac mortality rate 2.0% and 8.5%, respectively (pϭ0.044), stent thrombosis rate 0 vs. 4.3% (pϭ0.039). Conclusions: As compared to clopidogrel, prasugrel improves clinical outcome in all comers patients with ULMD receiving EES. In pts with STEMI undergoing primary PCI, procedural anticoagulation with Biv rather than HϩGPI is associated with reduced cardiac mortality among pts with as well as those w/o major bleeding, a benefit which may be attributed to prevention of thrombocytopenia.
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Assessment of 30-Day Rehospitalization For Acute Myocardial Infarction In Patients With Acute Coronary Syndrome Who Received Percutaneous Coronary Intervention: A Comparative Effectiveness Study Of Clopidogrel And Prasugrel
Jay Bae 1 , Douglas Faries 1 , Frank Ernst 2 , Craig Lipkin 2 , Zhenxiang Zhao 1 , Chad Moretz 2 1 Eli Lilly and Company, Indianapolis, IN, 2 Premier Research Services, Charlotte, NC Background: A 30-day rehospitalization rate for acute myocardial infarction (AMI) following hospital discharge among patients with acute coronary syndrome (ACS) who have received percutaneous coronary intervention (PCI) has been adopted as a hospital quality and performance measure. This study sought to compare 30-and 90-day AMI-related rehospitalization rates between ACS-PCI patients receiving clopidogrel versus those receiving prasugrel. Methods: The study endpoint was pre-specified, and analysis was done under blinding. Using a large geographically diverse US database maintained by PREMIER, the study analyzed AMI-related rehospitalizations among ACS-PCI patients receiving either clopidogrel or prasugrel between July 2009 and June 2011. Analysis included patients treated with prasugrel who were on-label and clopidogrel-treated patients who would have been eligible for prasugrel treatment per the label. Treatment differences in rehospitalization rate at 30 and 90 days were analyzed. Unadjusted comparisons used chi-square tests. Multivariate logistic regression analyses adjusted for baseline patient differences using propensity score stratification. Results: Data were available for 83,576 patients, of which 74,163 received clopidogrel and 9,403 received prasugrel. For clopidogrel and prasugrel, respectively, the observed AMI-related rehospitalization rates were 4.74% and 3.85% at 30 days (Pϭ0.0001) and 6.27% and 5.13% at 90 days (PϽ0.0001). Prasugrel was associated with approximately 10% lower odds of AMI-related rehospitalization (Odds ratioϭ0.892 at 30 days [95% CI: 0.798-0.998]; Odds ratioϭ0.901 at 90 days [95% CI: 0.817-0.994]). Conclusions: Compared to clopidogrel-treated patients, prasugrel-treated patients experienced fewer rehospitalizations for AMI at 30 days and 90 days following ACS-PCI discharge. Similar results were obtained after adjusting for patient demographics and clinical characteristics. The potential for unmeasured confounder bias is a limitation in this real-world observational research. 
